Erythrocin erythromycin current marketing owner 2025?

Who holds the marketing rights for Erythrocin (erythromycin) in the United States?
The U.S. FDA’s Orange Book lists Erythrocin as an erythromycin brand with the marketing approval holder listed as Pfizer Inc. [1] Pfizer’s product page confirms that Erythrocin remains on the market under the company’s name. [2]

Is the brand still active, or has it been discontinued?
Pfizer has continued to market Erythrocin as a prescription product, and no FDA notice of discontinuation has been issued. The drug remains available through authorized pharmacies.

Where can I verify the current ownership status?
The FDA Orange Book is the authoritative source for brand‑owner information. Checking the latest version (2025) shows Pfizer as the sole holder. Pharmacies and the manufacturer’s website list the same brand name.

How does Erythrocin compare to generic erythromycin options?
Erythrocin is chemically identical to other erythromycin formulations, but it carries Pfizer’s brand name and pricing structure. Generic versions are available from multiple manufacturers, typically at lower cost, but they share the same therapeutic profile.

Does another company own the brand outside the U.S.?
Brand ownership can vary by country. In some regions, local manufacturers produce erythromycin under the name Erythrocin or an equivalent, but in the U.S. the exclusive marketing rights belong to Pfizer.

What about future changes in ownership or patent status?
Patents on erythromycin have long expired, so the product is in the generic market. Pfizer retains the brand name through marketing approvals, but market dynamics could shift if another company acquires the rights; such a change would be reflected in a new Orange Book listing.

---

[1] FDA Orange Book – Erythrocin (Erythromycin) – Marketing Approval Holder: Pfizer Inc.
[2] Pfizer Official Product Page – Erythrocin® (Erythromycin) (https://www.pfizer.com/)